Stanley-Laman Group, Ltd. reported NEUROCRINE BIOSCIENC (NBIX) in 12 quarterly 13F filings from 2024 Q2 through 2026 Q1. Peak portfolio weight reached 0.81% in 2024 Q4. The latest visible filing shows NBIX at 0.45% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was Stanley-Laman Group, Ltd.'s position in NEUROCRINE BIOSCIENC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
NBIX was reported at 0.45% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
As of 2026 Q1 — sorted by position size
These are the practical questions this page is built to answer before you even open the full history table.
Stanley-Laman Group, Ltd. reported NBIX across 8 quarterly 13F filings, from 2024 Q2 through 2026 Q1.
The largest reported portfolio weight for NBIX was 0.81% in 2024 Q4.
The most recent filing on this page is 2026 Q1, when Stanley-Laman Group, Ltd. reported 27,549 shares, equal to 0.45% of portfolio, with an estimated market value of $3.6M.
The chart compares Stanley-Laman Group, Ltd.'s quarterly NBIX portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.